Overview

Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation study to determine the safety, maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of 188Re-PTI-6D2 in patients with metastatic melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
Pain Therapeutics